 | Up a level |
Cornely, O. A., Ostrosky-Zeichner, L., Rahav, G., Maher, R., Zeiher, B., Lee, M. and Perfect, J. (2015). Outcomes in Patients with Invasive Mold Disease Caused by Fusarium or Scedosporium spp. Treated with Isavuconazole: Experience from the VITAL and SECURE Trials. Mycoses, 58. S. 196 - 198. HOBOKEN: WILEY-BLACKWELL. ISSN 1439-0507
Marty, F. M., Perfect, J., Cornely, O. A., Mullane, K. M., Rahav, G., Lee, M., Ito, M., Maher, R., Zeiher, B. and Ostrosky-Zeichner, L. (2015). An open-label phase 3 study of isavuconazole (VITAL): focus on mucormycosis. Mycoses, 58. S. 198 - 200. HOBOKEN: WILEY-BLACKWELL. ISSN 1439-0507
Vehreschild, M. J. G. T., Vehreschild, J. J., Marty, F. M., Perfect, J., Ostrosky-Zeichner, L., Rahav, G., Zeiher, B., Lee, M., Maher, R., Lovell, C., Engelhardt, M. and Cornely, O. A. (2015). Primary treatment of invasive mucormycosis (IM) with isavuconazole (VITAL Study) or amphotericin formulations (FungiScopeTM): case matched analysis. Mycoses, 58. S. 197 - 198. HOBOKEN: WILEY-BLACKWELL. ISSN 1439-0507
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., Jenkin, G., Jensen, W., Kim, Y. -S., Yoshida, J., Gabryelski, L., Pedley, A., Eves, K., Tipping, R., Guris, D., Kartsonis, N. and Dorr, M. -B. (2017). Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N. Engl. J. Med., 376 (4). S. 305 - 318. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406